Partnership will showcase Genvor’s AI-accelerated peptide platform and sustainable agricultural solutions.
B2i Digital, Inc. announced that Genvor Inc. has joined the B2i Digital platform as a Featured Company. Based in Woodland, California, Genvor is an agricultural biotechnology innovator developing sustainable crop-protection solutions through AI-accelerated peptide design. Founded in 2018, the company is advancing a suite of antimicrobial, insecticidal, and nutrient-enhancing peptides built on its proprietary BioCypher Algorithm, which targets the estimated $220 billion in annual global crop losses caused by plant pathogens.
“We look forward to helping Genvor reach interested investors through our multi-channel digital marketing engine and targeted outreach campaigns,” said David Shapiro, CEO of B2i Digital. “I have been particularly impressed with Genvor’s leadership and their ability to clearly articulate the growing demand for biological solutions in agriculture and how their platform is designed to meet that need.”
Read More: SalesTechStar Interview with Sahil Rekhi, Chief Revenue Officer at Graia
Genvor’s BioCypher Algorithm leverages more than 50,000 designed peptides and over 30 years of foundational research to produce targeted solutions for major agricultural challenges. The platform has demonstrated broad-spectrum efficacy, including 76%–98% reductions in total aflatoxin contamination in transgenic corn seeds across pathogens such as Aspergillus flavus and Fusarium species.
I’ve been particularly impressed with Genvor’s leadership and their ability to clearly articulate the growing demand for biological solutions in agriculture and how their platform meets that need.”
— David Shapiro, CEO of B2i Digital, Inc.
“As we continue our accelerated momentum with recently issued patents, active partnership discussions, and a growing pipeline, this is a key moment to expand investor engagement,” said Chad Pawlak, CEO of Genvor. “We look forward to leveraging B2i Digital’s platform to connect with investors who understand the growing demand for sustainable crop protection and the value of our licensing-first business model.”
Genvor maintains a growing intellectual property portfolio, including two issued U.S. patents and one pending application covering 24 proprietary peptides. In November 2025, the company announced the issuance of U.S. Patent No. 12,458,684 for transgenic corn expressing antifungal peptide AGM182, co-assigned to Genvor Inc. and the United States Department of Agriculture (USDA). This patent represents a significant milestone in validating the commercial potential of Genvor’s seed-trait technologies for major row crops.
Genvor’s development pipeline spans multiple crops, including corn, citrus, rice, soybeans, cotton, flax, and potato, with applications across both foliar spray solutions and seed traits. The company is currently engaged with major agricultural companies on joint venture evaluations and commercialization discussions.
Read More: Beyond CRM: How SalesTech is Shaping the Future of Deal Management?